{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T09:33:02Z","timestamp":1649064782798},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T00:00:00Z","timestamp":1453420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00347-015-0214-4","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T14:59:52Z","timestamp":1453474792000},"page":"589-595","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analyse kardiovaskul\u00e4rer Erkrankungen nach der Upload-Phase mit intravitrealem Ranibizumab oder Bevacizumab bei Patienten mit exsudativer altersbedingter Makuladegeneration"],"prefix":"10.1007","volume":"113","author":[{"given":"C.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dschietzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"issue":"7","key":"214_CR1","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","volume":"286","author":"JT Andersen","year":"2011","unstructured":"Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahms\u00e9n L, Ekblad C (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286(7):5234\u20135241","journal-title":"J Biol Chem"},{"key":"214_CR2","unstructured":"AVASTIN (bevacizumab) solution for intravenous infusion prescribing information. http:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf . Zugegriffen: M\u00e4rz 2014"},{"key":"214_CR3","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"R Avery","year":"2014","unstructured":"Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R, Couvillion S, Nasir M, Rabena M, Le K, Maia M, Visich J (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641","journal-title":"Br J Ophthalmol"},{"key":"214_CR4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen T, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to lucas treat-and-extend protocol. Ophthalmology 122:146\u2013152","journal-title":"Ophthalmology"},{"key":"214_CR5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00228-014-1755-1","volume":"70","author":"C Biagi","year":"2014","unstructured":"Biagi C, Conti V, Montanaro N, Melis M, Buccellato E, Donati M, Covezzoli A, Amato R, Pazzi L, Venegoni M, Vaccheri A, Motola D (2014) Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. Eur J Clin Pharmacol 70:1505\u20131512","journal-title":"Eur J Clin Pharmacol"},{"key":"214_CR6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","volume":"116","author":"DS Boyer","year":"2009","unstructured":"Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731\u20131739","journal-title":"Ophthalmology"},{"issue":"6","key":"214_CR7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archopht.1989.01070010869032","volume":"107","author":"NM Bressler","year":"1989","unstructured":"Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR (1989) The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 107(6):847\u2013852","journal-title":"Arch Ophthalmol"},{"key":"214_CR8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","volume":"29","author":"TK Choueiri","year":"2011","unstructured":"Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FAB (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632\u2013638","journal-title":"J Clin Oncol"},{"issue":"3","key":"214_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08820530701543024","volume":"22","author":"RM Dafer","year":"2007","unstructured":"Dafer RM, Schneck M, Friberg TR, Jay WM (2007) Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 22(3):201\u2013204","journal-title":"Semin Ophthalmol"},{"key":"214_CR10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ophtha.2006.07.045","volume":"114","author":"Y Duan","year":"2007","unstructured":"Duan Y, Mo J, Klein R, Scott IU, Lin HM, Caulfield J, Patel M, Liao D (2007) Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 114:732\u2013737","journal-title":"Ophthalmology"},{"key":"214_CR11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1350-9462(00)00023-9","volume":"20","author":"JR Evans","year":"2001","unstructured":"Evans JR (2001) Risk factors for age-related macular degeneration. Prog Retin Eye Res 20:227\u2013253","journal-title":"Prog Retin Eye Res"},{"key":"214_CR12","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","volume":"280","author":"N Ferrara","year":"2001","unstructured":"Ferrara N (2001) Role of vascular endothelial growth factorin regulation of physiological angionesis. Am J Physiol Cell Physiol 280:C1358\u2013C1366","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"214_CR13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90(11):1344\u20131349","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"214_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/STROKEAHA.109.571000","volume":"41","author":"CC Hu","year":"2010","unstructured":"Hu CC, Ho JD, Lin HC (2010) Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 41(4):613\u2013617","journal-title":"Stroke"},{"issue":"23","key":"214_CR15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colon cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"key":"214_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0420.2006.00819.x","volume":"85","author":"M Kernt","year":"2007","unstructured":"Kernt M, Neubauer AS, Kampik A (2007) Intravitreal bevacizumab (Avastin\u00ae) is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85:119\u2013120","journal-title":"Acta Ophthalmol Scand"},{"issue":"11","key":"214_CR17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00347-007-1569-y","volume":"104","author":"M Kernt","year":"2007","unstructured":"Kernt M, Welge-L\u00fcssen U, Yu A, Neubauer AS, Kampik A (2007) Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 104(11):965\u2013971","journal-title":"Ophthalmologe"},{"key":"214_CR18","first-page":"1868","volume":"15","author":"JH Kim","year":"2009","unstructured":"Kim JH, Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS (2009) Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation. Mol Vis 15:1868\u20131875","journal-title":"Mol Vis"},{"key":"214_CR19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","volume":"99","author":"BE Klein","year":"1992","unstructured":"Klein BE, Klein R, Linton KL (1992) Prevalence of age-related lens maculopathy: the Beaver Dam Eye Study. Ophthalmology 99:933\u2013943","journal-title":"Ophthalmology"},{"issue":"3","key":"214_CR20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0161-6420(93)31634-9","volume":"100","author":"R Klein","year":"1993","unstructured":"Klein R, Klein B, Franke T (1993) The relationship of cardiovascular disease and its risk factors to age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 100(3):406\u2013414","journal-title":"Ophthalmology"},{"key":"214_CR21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0161-6420(03)00599-2","volume":"110","author":"R Klein","year":"2003","unstructured":"Klein R, Klein B, Tomany S, Cruickshanks K (2003) The association of cardiovascular disease with the long-term incidence of age-related maculopathy. Ophthalmology 110:1273\u20131280, 636\u2013643","journal-title":"Ophthalmology"},{"key":"214_CR22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/archopht.121.5.674","volume":"121","author":"R Klein","year":"2003","unstructured":"Klein R, Klein B, Tomany S, Cruickshanks K (2003) Association of emphysema, gout and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol 121:674\u2013678","journal-title":"Arch Ophthalmol"},{"key":"214_CR23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ajo.2003.10.020","volume":"137","author":"R Klein","year":"2004","unstructured":"Klein R, Klein B, Tomany S, Wong T (2004) The relation of microvascular characteristics to age-related eye disease: the Beaver Dam Eye Study. Am J Ophthalmol 137:435\u2013444","journal-title":"Am J Ophthalmol"},{"key":"214_CR24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","volume":"114","author":"R Klein","year":"2007","unstructured":"Klein R, Klein B, Knudtson M, Meuer S, Swift M, Gangnon R (2007) Fifteen-Year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 114:253\u2013262","journal-title":"Ophthalmology"},{"key":"214_CR25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, Schmetterer L, Boltz A, Told R, V\u00e9csei-Marlovits V, Egger S, Sch\u00f6nherr U, Haas A, Ansari-Shahrezaei S, Binder S, for the MANTA Research Group (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97:266\u2013271","journal-title":"Br J Ophthalmol"},{"key":"214_CR26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-2005-858315","volume":"222","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ (2005) Treatment of neovascular age-related macular degeneration with Ranibizumab\/Lucentis\u00ae. Klin Monatsbl Augenheilkd 222:480\u2013484","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"6","key":"214_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112(6):1035\u20131047","journal-title":"Ophthalmology"},{"issue":"1","key":"214_CR28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jech.47.1.42","volume":"47","author":"RA Mitchell","year":"1993","unstructured":"Mitchell RA (1993) Prevalence of age related macular degeneration in persons aged 50 years and over resident in Australia. J Epidemiol Community Health 47(1):42\u201345","journal-title":"J Epidemiol Community Health"},{"key":"214_CR29","doi-asserted-by":"crossref","first-page":"2002.e1","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"AA Moshfeghi","year":"2006","unstructured":"Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002.e1\u2013e12","journal-title":"Ophthalmology"},{"issue":"1","key":"214_CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","volume":"27","author":"J Nov\u00e1k","year":"2014","unstructured":"Nov\u00e1k J, Nov\u00e1k M, Kruzliak P (2014) Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens 27(1):3\u201313","journal-title":"Am J Hypertens"},{"issue":"3","key":"214_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","volume":"49","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49(3):287\u2013297","journal-title":"Acta Oncol"},{"key":"214_CR32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nbt1004-1198","volume":"22","author":"M Ratner","year":"2004","unstructured":"Ratner M (2004) Genentech discloses safety concers over Bevacizumab. Nat Biotechnol 22:1198","journal-title":"Nat Biotechnol"},{"issue":"3","key":"214_CR33","first-page":"361","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19(3):361\u2013372","journal-title":"Ophthalmol Clin North Am"},{"key":"214_CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","volume":"99","author":"K Schmid","year":"2014","unstructured":"Schmid K, Bachmann L, F\u00e4s L, Kessels A, Job O, Thiel M (2014) Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 99:141\u2013146","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"214_CR35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","volume":"22","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK, Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22(6):1404\u20131412","journal-title":"Ann Oncol"},{"issue":"2","key":"214_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s13524-015-0372-7","volume":"52","author":"A Sol\u00e9-Aur\u00f3","year":"2015","unstructured":"Sol\u00e9-Aur\u00f3 A, Michaud PC, Hurd M, Crimmins E (2015) Disease incidence and mortality among older Americans and Europeans. Demography 52(2):593\u2013611. doi: 10.1007\/s13524-015-0372-7","journal-title":"Demography"},{"issue":"10","key":"214_CR37","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2009.03.046","volume":"116","author":"C Sun","year":"2009","unstructured":"Sun C, Klein R, Wong TY (2009) Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 116(10):1913\u20131919","journal-title":"Ophthalmology"},{"issue":"1","key":"214_CR38","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1517\/14712598.5.1.S37","volume":"5","author":"D Ternant","year":"2005","unstructured":"Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37\u2013S47","journal-title":"Expert Opin Biol Ther"},{"issue":"20","key":"214_CR39","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"The CATT Research Group","year":"2011","unstructured":"The CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908","journal-title":"N Engl J Med"},{"key":"214_CR40","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"The IVAN Study Investigators","year":"2012","unstructured":"The IVAN Study Investigators (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology 119:1399\u20131141","journal-title":"Ophthalmology"},{"key":"214_CR41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archopht.122.5.750","volume":"122","author":"SC Tomany","year":"2004","unstructured":"Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD (2004) Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Stud. Arch Ophthalmol 122:750\u2013757","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"214_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0161-6420(95)31034-2","volume":"102","author":"JR Vingerling","year":"1995","unstructured":"Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102(2):205\u2013210","journal-title":"Ophthalmology"},{"key":"214_CR43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.epirev.a036198","volume":"17","author":"JR Vingerling","year":"1995","unstructured":"Vingerling JR, Klaver CC, Hofman A, de Jong PT (1995) Epidemiology of age-related maculopathy. Epidemiol Rev 17:347\u2013360","journal-title":"Epidemiol Rev"},{"key":"214_CR44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ophtha.2006.07.017","volume":"114","author":"J Wang","year":"2007","unstructured":"Wang J, Rochtchina E, Lee A, Chia E, Smith W, Cumming R, Mitchell P (2007) Ten-Year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 114:92\u201398","journal-title":"Ophthalmology"},{"issue":"8","key":"214_CR45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0b013e31817e100f","volume":"28","author":"LJ Wong","year":"2008","unstructured":"Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS (2008) Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 28(8):1151\u20131158","journal-title":"Retina"},{"issue":"5","key":"214_CR46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427\u2013434","journal-title":"N Engl J Med"},{"issue":"6","key":"214_CR47","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.ATV.20.6.1512","volume":"20","author":"I Zachary","year":"2000","unstructured":"Zachary I, Mathur A, Yla-Herttuala S, Martin J (2000) Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 20(6):1512\u20131520","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"214_CR48","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1167\/iovs.15-16686","volume":"56","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Bechrakis NE, Stattin M, Kirchmair R, Ulmer H, Kralinger MT, Kieselbach GF (2015) Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. Invest Ophthalmol Vis Sci 56(5):3279\u20133286","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"214_CR49","first-page":"899","volume":"252","author":"J Zerbib","year":"2014","unstructured":"Zerbib J, Delcourt C, Puche N, Querques G, Cohen SY, Sahel J, Korobelnik JF, Le Goff M, Souied EH (2014) Risk factors for exudative age-related macular degeneration in a large French case-control study. Graefes Arch Clin Exp Ophthalmol 252:899\u2013907","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-015-0214-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-015-0214-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-015-0214-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T22:58:12Z","timestamp":1567551492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-015-0214-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1007\/s00347-015-0214-4","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]}}}